Ignite Creation Date:
2024-05-06 @ 5:14 PM
Last Modification Date:
2024-10-26 @ 2:25 PM
Study NCT ID:
NCT05244993
Status:
UNKNOWN
Last Update Posted:
2022-07-12
First Post:
2022-02-08
Brief Title:
AK105 Plus Anlotinib Hydrochloride Combined With Albumin Paclitaxel as a First-line Therapy in Patients With Advanced Triple-negative Breast Cancer
Sponsor:
Liaoning Tumor Hospital Institute
Organization:
Liaoning Tumor Hospital Institute
Study Overview
Official Title:
AK105 Plus Anlotinib Hydrochloride Combined With Albumin Paclitaxel as a First-line Therapy in Patients With Advanced Triple-negative Breast Cancer
Status:
UNKNOWN
Status Verified Date:
2022-07
Last Known Status:
NOT_YET_RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This trial used a multicentre single-arm design in which patients were treated with AK105 plus Anlotinib Hydrochloride combined with albumin paclitaxel Patients included in this trial were advanced breast cancer with hormone receptor negative and Her2 negative The primary endpoint is ORR and the secondary endpoint is DCR PFS OS and safety
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None